Substance / Medication

Terazosin

Overview

Active Ingredient
terazosin
RxNorm CUI
37798

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

3 trials linked to this intervention

3
Total Trials
0
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
WITHDRAWN: Terazosin for benign prostatic hyperplasia.
Wilt Timothy J, Howe R William, Rutks Indy et al. · Cochrane Database Syst Rev · 2011
PMID: 21901686Meta-AnalysisFull text (PMC)
Terazosin for benign prostatic hyperplasia.
Wilt T J, Howe R W, Rutks I R et al. · Cochrane Database Syst Rev · 2002
PMID: 12519611Meta-Analysis
Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia.
Boyle P, Robertson C, Manski R et al. · Urology · 2001
PMID: 11711348Meta-Analysis
Bioequivalence study of two formulations of terazosin hydrochloride capsule in healthy Chinese subjects under fasting and fed conditions.
Fan Lian-Lian, Li Mu-Peng, Wu Tong et al. · Int J Clin Pharmacol Ther · 2022
PMID: 34672254RCT
A pilot to assess target engagement of terazosin in Parkinson's disease.
Schultz Jordan L, Brinker Alivia N, Xu Jia et al. · Parkinsonism Relat Disord · 2022
PMID: 34894470RCTFull text (PMC)
Simple and fast LC-MS/MS method for quantification of terazosin in human plasma and application to bioequivalence study.
Loh Gabriel Onn Kit, Wong Emily Yii Ling, Tan Yvonne Tze Fung et al. · J Chromatogr B Analyt Technol Biomed Life Sci · 2021
PMID: 33429127RCT
Effect of terazosin on sweating in patients with major depressive disorder receiving sertraline: a randomized controlled trial.
Ghaleiha Ali, Shahidi Kadijeh Moghadasian, Afzali Saeed et al. · Int J Psychiatry Clin Pract · 2013
PMID: 22731399RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Terazosin (substance)
SNOMED CT
387068008
UMLS CUI
C0076107
RxNorm CUI
37798

Clinical Data

This intervention maps to 8 entities in the Ltrl knowledge graph.

4
Conditions
1
Biomarkers
2
Specialists
0
Symptoms
3
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.